Research Activities During the Fellowship
Panu Wetwittayakhlang (6/10 papers as 1st author)
- Advanced combination therapy: is it the best way to break the therapeutic ceiling? Wetwittayakhlang P, Lakatos PL.Therap Adv Gastroenterol. 2024 Oct 24;17:17562848241272995. doi: 10.1177/17562848241272995. eCollection 2024.PMID: 39474440 Free PMC article.
- Management of ulcerative colitis: where are we at and where are we heading? Abbas A, Di Fonzo DMP, Wetwittayakhlang P, Al-Jabri R, Lakatos PL, Bessissow T.Expert Rev Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1080/17474124.2024.2422370. Online ahead of print.PMID: 39470444
- How close are we to a success stratification tool for improving biological therapy in ulcerative colitis? Wetwittayakhlang P, Kotrri G, Bessissow T, Lakatos PL.Expert Opin Biol Ther. 2024 Jun;24(6):433-441. doi: 10.1080/14712598.2024.2371049. Epub 2024 Jun 26.PMID: 38903049 Review.
- Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Bacsur P, Wetwittayakhlang P, Resál T, Földi E, Vasas B, Farkas B, Rutka M, Bessissow T, Afif W, Bálint A, Fábián A, Bor R, Szepes Z, Farkas K, Lakatos PL, Molnár T.Therap Adv Gastroenterol. 2024 Mar 21;17:17562848241239606. doi: 10.1177/17562848241239606. eCollection 2024.PMID: 38524790 Free PMC article.
- Unravelling the Smoke Trail: Maternal Smoking, Childhood Exposure, and their Impact on Inflammatory Bowel Diseases. Wetwittayakhlang P, Lakatos PL.J Crohns Colitis. 2024 May 31;18(5):659-660. doi: 10.1093/ecco-jcc/jjae032.PMID: 38498342 No abstract available.
- Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials. Wetwittayakhlang P, Bessissow T, Lakatos PL.Expert Opin Emerg Drugs. 2024 Mar;29(1):19-34. doi: 10.1080/14728214.2024.2303116. Epub 2024 Jan 11.PMID: 38193191 Review.
- Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Al-Jabri R, Wetwittayakhlang P, Lakatos PL.J Clin Med. 2023 Nov 27;12(23):7343. doi: 10.3390/jcm12237343.PMID: 38068395 Free PMC article.
- Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi T, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T.Inflamm Bowel Dis. 2024 May 2;30(5):768-779. doi: 10.1093/ibd/izad135.PMID: 37542737 Free PMC article.
- Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Dig Liver Dis. 2024 Jan;56(1):35-42. doi: 10.1016/j.dld.2023.06.022. Epub 2023 Jul 5.PMID: 37419726
- Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis: A Population-Based Cohort Between 1977-2020. Wetwittayakhlang P, Golovics PA, Gonczi L, Lakatos L, Lakatos PL; VESZPREM EPIDEMIOLOGY STUDY GROUP.Clin Gastroenterol Hepatol. 2024 Jan;22(1):191-193.e3. doi: 10.1016/j.cgh.2023.03.022. .PMID: 37004972
Adnan Abbas (1/1 papers as 1st author)
- Management of ulcerative colitis: where are we at and where are we heading? Abbas A, Di Fonzo DMP, Wetwittayakhlang P, Al-Jabri R, Lakatos PL, Bessissow T. Expert Rev Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1080/17474124.2024.2422370. Online ahead of print.PMID: 39470444